A 2026 review article published in Therapeutic Advances in Medical Oncology by researchers at Case Western Reserve University’s Seidman Cancer Center provides a comprehensive update on how immunotherapy has fundamentally changed the treatment landscape for pleural mesothelioma, the aggressive asbestos-caused cancer that affects the lining of the lungs.
Pleural Mesothelioma: A Disease With Few Options Until Now
For decades, malignant pleural mesothelioma offered patients very limited treatment options. The standard of care for unresectable disease was a combination of platinum-based chemotherapy and pemetrexed, established in a 2003 clinical trial that showed a response rate of only 41% and a median overall survival of just over a year. The five-year survival rate for mesothelioma remains approximately 15%, and outcomes vary significantly depending on the tumor’s histologic subtype, with the epithelioid subtype carrying a more favorable prognosis than the sarcomatoid or biphasic subtypes.
The Immunotherapy Revolution
The introduction of immune checkpoint inhibitors has fundamentally altered how oncologists approach this disease. These drugs work by releasing a kind of “brake” on the immune system, restoring the ability of the body’s own cytotoxic T cells to recognize and attack tumor cells. The review traces how this class of medications became a cornerstone of first-line mesothelioma treatment.
The pivotal moment came with the CheckMate 743 trial, which randomized previously untreated patients with unresectable mesothelioma to receive either the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) or standard chemotherapy. The combination immunotherapy arm achieved a median overall survival of 18.1 months compared to 14.1 months for chemotherapy, and the survival benefit was most pronounced in patients with non-epithelioid histology — a subgroup that had previously been particularly difficult to treat, with median survival of only 8.8 months on chemotherapy compared to 18.1 months on immunotherapy. These results led to FDA approval of the combination for first-line treatment of unresectable mesothelioma.
For patients who have already received chemotherapy, the review describes several clinical trials showing that immunotherapy can also provide benefit in the relapsed and refractory setting. Pembrolizumab has demonstrated activity in both PD-L1 positive and negative tumors, with durable responses observed regardless of PD-L1 status — a clinically important finding. The most recent FDA-approved immunotherapy for metastatic mesothelioma is pembrolizumab (Keytruda), which received approval based on data demonstrating clinical benefit in previously treated patients.
Searching for Biomarkers and the Right Patients
A critical challenge the review highlights is identifying which patients are most likely to respond to immunotherapy. PD-L1 expression, tumor mutational burden, and tumor histology have all been studied as potential predictive markers, but none has proven sufficiently reliable on its own to guide treatment decisions. Mesothelioma tumors generally have a low mutational burden and a complex immunosuppressive tumor microenvironment, which presents ongoing challenges for immune-based therapies. The authors note an urgent need for prospective studies to identify clinically relevant genomic and transcriptomic biomarkers that can more precisely guide treatment selection.
Emerging Approaches on the Horizon
Beyond established checkpoint inhibitors, the review surveys a broad range of emerging immunotherapy strategies currently under investigation, including dendritic cell vaccines, CAR-T cell therapies targeting mesothelin (a protein overexpressed in mesothelioma), oncolytic viruses administered directly into the pleural space, and combinations of checkpoint inhibition with radiation therapy. Early-phase clinical trials of several of these approaches have demonstrated safety and feasibility, and some have shown promising signals of clinical activity. These investigational strategies represent the leading edge of what may become the next generation of treatment advances for mesothelioma patients.
What This Means for Mesothelioma Victims
This review underscores that mesothelioma research is actively advancing, and that patients diagnosed today have more treatment options than ever before. But it also reinforces a fundamental truth that mesothelioma victims and their families deserve to understand: this is a disease caused by asbestos exposure.
Every case of malignant pleural mesothelioma can be traced back to inhaled asbestos fibers — fibers that companies manufactured, distributed, and used in workplaces for decades while often concealing known dangers from the workers and consumers who were exposed.
If you or a loved one has been diagnosed with mesothelioma, legal accountability may be available. The Lanier Law Firm’s mesothelioma lawyers have the experience and resources to investigate your asbestos exposure history and pursue the full compensation you deserve.
Contact us today for a free consultation to explore legal options that could provide much needed financial relief and cover the costs of treatment, medical bills, pain and suffering, and more.
Reference: Zhang AL, Hsu ML. Immunotherapy advances in pleural mesothelioma. Therapeutic Advances in Medical Oncology. 2026;18:1–12.